Loading…
Loading…
New York, New York--(Newsfile Corp. - July 22, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of GRAIL, Inc. (NASDAQ: GRAL) between May 13, 2025 and February 19, 2026, inclusive (the "Class Period"), of the important August 4, 2026 lead plaintiff deadline. SO WHAT: If you purchased GRAIL common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Grail, Inc. (GRAL) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit PR Newswire BEN
BENSALEM, Pa., July 22, 2026 /PRNewswire/ -- The Law Offices of Howard G.
Deadline Alert: GRAL Investors Who Lost Money After Grail's NHS-Galleri Trial Failed Its Primary Endpoint Have Until August 4, 2026 to Seek Lead Plaintiff Appointment in Securities Class Action NEW YORK, July 22, 2026 /PRNewswire/ -- IMPORTANT DATE: August 4, 2026. Investors who purchased Grail, Inc. (NASDAQ: GRAL) securities between May 13, 2025 and February 19, 2026 and wish to seek appointment as lead plaintiff must file a motion by this date.
NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds GRAIL, Inc. (“GRAIL” or the “Company”) (NASDAQ: GRAL) investors of the August 4, 2026 deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join The GRAIL Class Action Lawsuit : Do you, or did you, own shares of GRAIL, Inc. (NASDAQ: GRAL)?
NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against GRAIL, Inc. (NASDAQ:GRAL) and certain of the Company's senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws. If you invested in GRAIL, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/grail-class-action-lawsuit.
SAN FRANCISCO, July 22, 2026 /PRNewswire/ -- National shareholder rights firm Hagens Berman is investigating claims in a pending class action alleging violations of U.S. securities laws by GRAIL, Inc. (NASDAQ: GRAL). The suit contends the company misled investors regarding the clinical design and efficacy of its landmark NHS-Galleri cancer screening trial.
SAN FRANCISCO, July 21, 2026 /PRNewswire/ -- National shareholder rights firm Hagens Berman is investigating claims in a pending class action alleging violations of U.S. securities laws by GRAIL, Inc. (NASDAQ: GRAL). The suit contends the company misled investors regarding the clinical design and efficacy of its landmark NHS-Galleri cancer screening trial.
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for GRAL and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.